Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 334.50
Bid: 331.50
Ask: 333.00
Change: 6.00 (1.83%)
Spread: 1.50 (0.452%)
Open: 323.00
High: 344.50
Low: 323.00
Prev. Close: 328.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: Numis cuts Kingfisher but raises Next

Tue, 11th Oct 2022 09:33

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

----------

FTSE 100

----------

Citigroup raises Centrica to 'buy' (neutral) - price target 81 (97) pence

----------

Citigroup raises Compass price target to 2,260 (2,170) pence - 'buy'

----------

Deutsche Bank raises Coca-Cola HBC target to 2,750 (2,700) pence - 'buy'

----------

Bernstein cuts Tesco price target to 250 (330) pence - 'outperform'

----------

Credit Suisse raises Anglo American target to 3,440 (3,290) pence - 'outperform'

----------

Credit Suisse cuts Antofagasta price target to 1,020 (1,040) pence - 'neutral'

----------

Credit Suisse raises Fresnillo price target to 650 (630) pence - 'underperform'

----------

Credit Suisse raises Rio Tinto price target to 5,800 (5,600) pence - 'outperform'

----------

Credit Suisse raises Glencore price target to 760 (720) pence - 'outperform'

----------

Credit Suisse cuts Severn Trent price target to 2,680 (2,800) pence - 'neutral'

----------

JPMorgan raises DS Smith price target to 388 (378) pence - 'overweight'

----------

Credit Suisse cuts Rightmove price target to 490 (608) pence - 'neutral'

----------

JPMorgan cuts Barclays price target to 180 (200) pence - 'neutral'

----------

JPMorgan cuts NatWest price target to 300 (350) pence - 'neutral'

----------

JPMorgan cuts Lloyds Banking price target to 56 (64) pence - 'overweight'

----------

Numis cuts Kingfisher to 'sell' (reduce) - price target 150 (215) pence

----------

Numis raises Next to 'buy' (add) - price target 6,800 (7,000) pence

----------

FTSE 250

----------

HSBC cuts Sirius Real Estate price target to 124 (138) pence - 'buy'

----------

JPMorgan cuts Virgin Money UK price target to 165 (200) pence - 'neutral'

----------

Barclays cuts Moneysupermarket.com target to 220 (230) pence - 'equal weight'

----------

Barclays cuts Future price target to 1,975 (2,500) pence - 'overweight'

----------

Berenberg cuts Marshalls price target to 280 (380) pence - 'hold'

----------

JPMorgan cuts Johnson Matthey price target to 2,150 (2,600) pence - 'neutral'

----------

Goldman Sachs cuts TI Fluid price target to 132 (179) pence - 'neutral'

----------

SMALL CAP

----------

Jefferies reinitiates ITM Power with 'buy' - price target 185 pence

----------

Jefferies reinitiates Ceres Power with 'hold' - price target 365 pence

----------

Citigroup cuts Ceres Power price target to 800 (1500) pence - 'buy'

----------

Barclays cuts Just Eat Takeaway target to 1,490 (1,940) pence - 'equal weight'

----------

RBC raises Oxford BioMedica price target to 1,110 (1,020) pence - 'outperform'

----------

Barclays starts Glenveagh Properties with 'overweight' - price target 1.20 EUR

----------

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
28 Jan 2022 16:19

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

Read more
28 Jan 2022 12:13

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

Read more
28 Jan 2022 10:27

Oxford BioMedica to acquire 80% ownership of new US virus business

Oxford BioMedica to acquire 80% ownership of new US virus business

Read more
28 Jan 2022 09:56

Oxford Biomedica creates venture with Homology, launches £80m fundraise

(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.

Read more
17 Jan 2022 09:32

Oxford Biomedica starts search for new CEO as Dawson steps down

Oxford Biomedica starts search for new CEO as Dawson steps down

Read more
17 Jan 2022 07:10

Oxford Biomedica CEO John Dawson to step down

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.

Read more
5 Jan 2022 08:54

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Read more
5 Jan 2022 07:29

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

Read more
15 Dec 2021 09:33

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Read more
13 Dec 2021 10:03

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Read more
13 Dec 2021 07:31

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
30 Sep 2021 09:35

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

Read more
28 Sep 2021 09:40

LONDON BROKER RATINGS: Investec prefers 888 over Entain

LONDON BROKER RATINGS: Investec prefers 888 over Entain

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.